Beslutninger på Vestjysk Bank A/S’ ordinære generalforsamling den 9. marts 2023
Nasdaq Copenhagen A/S
I dag, den 9. marts 2023, afholdte banken ordinær generalforsamling med følgende dagsorden som tidligere offentliggjort:
- Bestyrelsens mundtlige beretning om Bankens virksomhed i det forløbne år
- Fremlæggelse af revideret årsrapport til godkendelse
- Beslutning om anvendelse af overskud eller dækning af underskud i henhold til den godkendte årsrapport
- Fremlæggelse af vederlagsrapport til vejledende afstemning
- Godkendelse af vederlag til bestyrelsen for det indeværende regnskabsår
- Valg af medlemmer til bestyrelsen, herunder formand og næstformand
- Valg af revisor
- Forslag fra bestyrelsen eller aktionærer
8.a. Bemyndigelse til bestyrelsen til at erhverve egne aktier
8.b Fornyelse af bestyrelsens bemyndigelse til at forhøje aktiekapitalen uden fortegningsret for eksisterende aktionærer (vedtægternes punkt 10.10)
8.c Fornyelse af bestyrelsens bemyndigelse til at forhøje aktiekapitalen med fortegningsret for eksisterende aktionærer (vedtægternes punkt 10.11)
8.d Ændring af bestyrelsens sammensætning (vedtægternes punkt 10.1)
8.e Fjernelse af binavn (vedtægternes punkt 1.2)
8.f Præcisering af vedtægternes punkt 9.7
8.g Bemyndigelse til dirigenten
- Eventuelt
Bestyrelsens beretning blev indledningsvist taget til efterretning og den reviderede årsrapport for 2022 samt bestyrelsens forslag om anvendelse af overskud i henhold til den godkendte årsrapport blev herefter vedtaget. Årets resultat anvendes derfor således:
- Udbetaling af udbytte på DKK 0,110061 pr. aktie, svarende til ca. 135,8 mio. kroner.
- Overførsel af DKK 20.460.000 til indehavere af hybrid kapital.
- Henlæggelse af DKK 387.108.000 til egenkapitalen.
Ved vejledende afstemning godkendte generalforsamlingen vederlagsrapporten for 2022, og herefter blev forslaget om vederlag til medlemmerne af bestyrelsen for det indeværende regnskabsår vedtaget. Endelig blev forslaget om vederlag for bæredygtighedsudvalget for regnskabsåret 2022 med tilbagevirkende kraft vedtaget.
De generalforsamlingsvalgte bestyrelsesmedlemmer vælges for ét år ad gangen, hvorfor valgperioden for sådanne bestyrelsesmedlemmer udløb på den ordinære generalforsamling. Kim Rønnow Duus, Gert Rinaldo Jonassen, Anna Bolette van Ingen Bro, Hanne Træholt Odegaard, Bent Ejnar Juul Simonsen, Jan Nordstrøm, og Lars Langhoff blev alle genvalgt. Kim Rønnow Duus blev genvalgt som formand for bestyrelsen. Derudover blev Gert Rinaldo Jonassen genvalgt som næstformand for bestyrelsen.
EY Godkendt Revisionspartnerselskab blev genvalgt som revisor for banken.
Forslagene i punkt 8.a. til og med 8.g. som fremsat af bestyrelsen blev alle vedtaget af generalforsamlingen som fremsat i indkaldelsen med den fuldstændige dagsorden den 9. februar 2023.
Dirigenten blev bemyndiget – med substitutionsret – til at anmelde det vedtagne til Erhvervsstyrelsen samt foretage de ændringer og tilføjelser heri, som måtte blive krævet af Erhvervsstyrelsen eller andre offentlige myndigheder.
En generalforsamlingsprotokol vil blive gjort tilgængelig på Vestjysk Banks hjemmeside www.vestjyskbank.dk senest 2 uger fra dags dato.
Vestjysk Bank A/S
Bestyrelsen
Vestjysk Bank A/S
Industrivej Syd 13C
7400 Herning
Telefon 96 63 20 00
CVR-nr. 34 63 13 28
www.vestjyskbank.dk
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)16.4.2024 23:30:00 CEST | Press release
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of StelaraSELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process used for the production of Stelara REYKJAVIK, ICELAND & PARSIPPANY, NJ — Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Unde
Atico Reports Consolidated Financial Results for 202316.4.2024 22:30:29 CEST | Press release
(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the year ended December 31, 2023, posting income from mining operations of $7.4 million and a net loss of $5.8 million. Production for the year at Atico’s El Roble mine totaled 13.2 million pounds (“lbs”) of copper and 10,149 ounces (“oz”) of gold in concentrate at a cash cost(1) of $2.04 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, "we had a challenging year overall, with the first half of the year facing lower than expected head grades and lower throughput due to mechanical and operational issues, coupled with a significant appreciation in the Colombian Peso throughout the year which materially increased our costs. Despite these challenges the team did a great job getting El Roble mine back on track in the
Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program16.4.2024 22:10:00 CEST | Press release
Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan extends the anticipated cash runway to the fourth quarter of 2025, through the readout from the Phase II DOVACC trial Oslo, April 16, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several c
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations16.4.2024 22:05:00 CEST | Press release
ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations. “FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families. The importance of accurately delivering this one-time gene therapy to the thalamus, while minimizing systemic exposure, is the precise use case of ClearPoint’s minimally invasive platform for gene and cell delivery,” stated Jeremy Stigall, Chief Business Officer at ClearPoin
Nokia Corporation: Repurchase of own shares on 16.04.202416.4.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 16 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 16.04.2024 Espoo, Finland – On 16 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL557,6403.17CEUX--BATE--AQEU--TQEX--Total557,6403.17 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of